Method for treating central nervous system disorders with substituted 2-imidazoline derivatives

Abstract

The present invention relates to a method for treating depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders which comprises administering to an individual a therapeutically effective amount of a compound of formula I

Description

Claims

1. A method for treating a disorder selected from the group consisting of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders which comprises administering to an individual a therapeutically effective amount of a compound of formula I

2. The method of claim 1, wherein X is N, and aryl is phenyl.

3. The method of claim 2, wherein the compound is selected from the group consisting of (4,5-dihydro-1H-imidazol-2-yl)-(2,6-dimethyl-phenyl)-amine or tautomer,(2,6-diethyl-phenyl) -(4,5-dihydro-1H-imidazol-2-yl)-amine or tautomer,(2,6-dibromo-phenyl)-imidazolidin-2-ylidene-amine or tautomer,(4,5-dihydro-1H-imidazol-2-yl)-(2-ethyl-6-methyl-phenyl)-amine or tautomer,(4,5-dihydro-1H-imidazol-2-yl)-(2-isopropyl-6-methyl-phenyl)-amine or tautomer,(5-chloro-2-methyl-phenyl)-imidazolidin-2-ylidene-amine or tautomer and3-[4-(4,5-dihydro-1H-imidazol-2-ylamino)-phenyl]-1-naphthalen-2-yl-propan-1-one or tautomer.

4. The method of claim 1, wherein X is N, and aryl/hetaryl is naphtha-1-yl, 5,6,7,8-tetrahydronaphthalen-1-yl or thiophen-3-yl

5. The method of claim 4, wherein the compound is selected from the group consisting of imidazolidin-2-ylidene-naphthalen-1-yl-amine or tautomer, (4,5-dihydro-1H-imidazol-2-yl)-(5,6,7,8-tetrahydro-naphthalen-1-yl)-amine trifluoro-acetate or tautomer and(2-chloro-4-methyl-thiophen-3-yl)-(4,5-dihydro-1H-imidazol-2-yl)-amine or tautomer.

6. The method of claim 1, wherein X is S and aryl is phenyl.

7. The method of claim 6, wherein the compound is 2-(2,6-dichloro-phenylsulfanyl)-4,5-dihydro-1H-imidazole.

8. The method of claim 1, wherein the disorder is schizophrenia.

9. The method of claim 1, wherein the disorder is Alzheimer's disease.

10. The method of claim 1, wherein the disorder is cognitive impairment.

11. A method for preparation of compounds of formula I

12. A pharmaceutical composition comprising a compound of formula I